BAFF,A newcomer to the lupus party

Lipsky PE Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity . Nat Immunol 2001; 2: 764—766.

Mackay F. , Woodcock SA , Lawton P. et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697—1710.

Novak AJ , Bram RJ , Kay NE , Jelinek DF Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002 ; 100: 2973—2979.

Toubi E. , Shoenfeld Y. BLyS/BAFF: a potential target in the treatment of active systemic lupus erythematosus . Isr Med Assoc J 2004; 6: 99—102.

Daridon C. , Youinou P. , Pers JO BAFF, APRIL, TWE-PRIL: who's who? Autoimmun Rev 2007 (in press).

Daridon C. , Devauchelle V. , Hutin P. et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007; 56: 1134—1144.

Litinskiy MB , Nardelli B. , Hilbert DM et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822—829.

Batten M. , Fletcher C. , Ng LG et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004; 172: 812—822.

Lesley R. , Xu Y. , Kalled SL et al. Reduced competitiveness of autoantigenengaged B cells due to increased dependence on BAFF. Immunity 2004 ; 20: 441—453.

Sims GP , Ettinger R. , Shirota Y. , Yarboro CH , Illei GG , Lipsky PE Identification and characterization of circulating human transitional B cells . Blood 2005; 105: 4390—4398.

Zhang J. , Roschke V. , Baker KP et al. Cutting edge: a role for B-lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6—10.

Becker-Merok A. , Nikolaisen C. , Nossent HC B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006; 15: 570—576.

Carter RH , Zhao H. , Liu X. et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3943—3954.

Roschke V. , Sosnovtseva S. , Ward CD et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314—4321.

Gavin AL , Ait-Azzouzene D. , Ware CF , Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003; 278: 38220—32228.

Baker KP , Edwards BM , Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48: 3253—3265.

Le Pottier L. , Bendaoud B. , Dueymes M. et al. BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer. J Clin Immunol 2007; 27: 257—265.

Ramanujam M. , Wang X. , Huang W. et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116: 724—734.

Nimmanapalli R. , Lyu MA , Du M. , Keating MJ , Rosenblum MG , Gandhi V. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 2007; 109: 2557—2564.

Lee CV , Hymowitz SG , Wallweber HJ et al. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 2006; 108: 3103—3111.